These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3908748)

  • 1. [Branhamella infection].
    Nagatake T
    Rinsho Byori; 1985 Aug; 33(8):884-91. PubMed ID: 3908748
    [No Abstract]   [Full Text] [Related]  

  • 2. [Respiratory tract infection with Branhamella catarrhalis].
    Matsumoto K; Nagatake T; Uzuka Y; Rikitomi N; Noguchi Y
    Nihon Naika Gakkai Zasshi; 1982 Dec; 71(12):1696-702. PubMed ID: 6984859
    [No Abstract]   [Full Text] [Related]  

  • 3. Branhamella catarrhalis: an unappreciated pulmonary pathogen.
    Roth RM; Gleckman RA; Hibert DM
    Am Fam Physician; 1984 Oct; 30(4):169-73. PubMed ID: 6333806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Refractory respiratory tract infections. 9. Chemotherapy of recent respiratory tract infections. a. Branhamella catarrhalis infection].
    Nagatake T; Rikitomi N; Tao M; Watanabe K; Mbaki N; Matsumoto K
    Nihon Rinsho; 1987 Mar; 45(3):604-10. PubMed ID: 3599486
    [No Abstract]   [Full Text] [Related]  

  • 5. Bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid.
    Ninane G; Joly J; Kraytman M; Piot P
    Lancet; 1978 Jul; 2(8083):257. PubMed ID: 79045
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.
    Alvarez S; Jones M; Holtsclaw-Berk S; Guarderas J; Berk SL
    Antimicrob Agents Chemother; 1985 Apr; 27(4):646-7. PubMed ID: 3873905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Branhamella catarrhalis: antibiotic susceptibility and beta-lactamase production.
    Brorson JE; Martinell J; Wilske H
    J Antimicrob Chemother; 1981 Feb; 7(2):208-9. PubMed ID: 6971288
    [No Abstract]   [Full Text] [Related]  

  • 8. Branhamella catarrhalis--an emerging human pathogen.
    Doern GV
    Diagn Microbiol Infect Dis; 1986 Mar; 4(3):191-201. PubMed ID: 3514103
    [No Abstract]   [Full Text] [Related]  

  • 9. Respiratory tract infection: epidemiology and surveillance.
    Jacobs MR
    J Chemother; 1997 May; 9 Suppl 3():10-7. PubMed ID: 9248976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic sensitivity of Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes and Branhamella catarrhalis isolated from upper respiratory tract infections in Sweden.
    Kallings I; Bengtsson S; Christensen P; Holm SE; Lind L; Kalin M
    Scand J Infect Dis Suppl; 1983; 39():100-5. PubMed ID: 6359377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections.
    Slevin NJ; Aitken J; Thornley PE
    Lancet; 1984 Apr; 1(8380):782-3. PubMed ID: 6143094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community-acquired lower respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors.
    Lode H
    Int J Clin Pract Suppl; 2002 Mar; (125):10-17; discussion 37-9. PubMed ID: 12014852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Microbiological and therapeutic considerations of Acinetobacter spp. infection].
    López-Brea M; Alarcón T; López S
    Rev Esp Quimioter; 1998 Jun; 11(2):110-7. PubMed ID: 9795295
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibiotic-sensitivity of Moraxella catarrhalis isolated from clinical materials in 1997-1998.
    Mikucka A; Janicka G; Krawiecka D; Kochanowska J
    Med Sci Monit; 2000; 6(2):300-4. PubMed ID: 11208326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between beta-lactamases production and resistance to beta-lactam antibiotics in clinical isolates of Enterobacteriaceae.
    Romero E; Pagani L; Perduca M; Mignatti P; Malfa S; Mills V
    Microbiologica; 1984 Jul; 7(3):209-18. PubMed ID: 6334220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
    You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
    J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
    [No Abstract]   [Full Text] [Related]  

  • 17. [Microbiol landscape and production of beta-lactamases with extended spectrum activity in patients with urinary tract infection].
    Zhevlakova IuA; Zakharova GV; Khokhlova OI; Ust'iantseva IM
    Klin Med (Mosk); 2009; 87(3):56-9. PubMed ID: 19469259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Beta-lactamase inhibitors. A progress indeed, but their combination with beta lactams is not a panacea].
    Denis F; Mounier M; Philippon A
    Rev Prat; 1994 Jan; 44(2):215-9. PubMed ID: 8178078
    [No Abstract]   [Full Text] [Related]  

  • 19. The emergence of resistance to beta-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution?
    Nichols L; Maki DG
    Chemioterapia; 1985 Feb; 4(1):102-9. PubMed ID: 3986938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evolution of resistance to beta-lactam inhibitors of beta-lactamases].
    Alóz JI
    Rev Esp Quimioter; 1998 Dec; 11(4):375-6. PubMed ID: 10336321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.